Integrative Preconception & Recurrent Pregnancy Loss Playbook: Luteal Progesterone Timing, CoQ10/NAC Protocols & Autoimmune Screening Before IVF

01Unexplained infertility vs. recurrent pregnancy loss: when to get evaluated

This playbook covers two related situations that need different workups.

Infertility

No pregnancy after 12 months of regular unprotected sex if you are under 35, or after 6 months if you are 35 or older. Evaluation should start right away if you are over 40, have irregular or absent periods, known endometriosis or tubal disease, or a partner with known sperm problems.

Unexplained infertility

Infertility where ovulation, open fallopian tubes, a normal uterine cavity and a normal semen analysis have all been confirmed. It accounts for roughly 15%–30% of couples evaluated. “Unexplained” means current tests found no cause, not that nothing is wrong.

Recurrent pregnancy loss (RPL)

Two or more failed clinical pregnancies, as defined by ASRM. ESHRE’s 2022 guideline uses two or more pregnancy losses. About 1%–2% of couples trying to conceive are affected.

The reassuring numbers matter. Even after three unexplained losses, the chance of a live birth in the next pregnancy is around 60%–70%, depending on age and number of prior losses. And for unexplained infertility, a significant share of couples conceive without treatment over the following year, which is why ASRM supports a stepwise approach rather than going straight to IVF for everyone.

Male factors contribute to roughly 40%–50% of infertility, so any evaluation that tests only the woman is incomplete. Age is the single strongest factor in egg quality and miscarriage risk, and no supplement or test changes that, which is why timing your evaluation matters more than optimizing any one marker.

Integrative preconception care is most useful in the months before trying or between losses: completing the workup, treating what is found, setting up evidence-based supplements for both partners, and avoiding expensive add-ons that do not improve live birth rates.

02Why 12-minute visits leave couples without answers

Short visits tend to fall into one of two failure modes: doing too little or doing the wrong things.

1. The partner is never tested. A semen analysis is inexpensive, fast and often decisive, yet many women go through months of cycle tracking before anyone asks for one.
2. “Wait another year.” Reassurance is appropriate for a 28-year-old after six months; it is harmful for a 38-year-old after six months, when ASRM advises evaluation.
3. Miscarriage is treated as bad luck every time. A single loss usually is chance, most often from embryo chromosomal errors. After two or more, an RPL workup is recommended, but many patients are not offered it until the third or fourth loss.
4. A day-21 progesterone becomes a diagnosis. A single progesterone level only shows whether ovulation happened. It does not diagnose “luteal phase defect,” but it is often used that way to justify progesterone that has no proven benefit in that setting.
5. Thyroid results are read without context. TSH is checked but TPO antibodies are not, or a TSH of 3.5 is ignored without discussing the evidence on either side.

The opposite failure happens in some cash-pay settings: large immune panels, natural killer cell tests and “egg quality” packages sold without evidence that they improve live birth rates.

A good integrative clinician sits between the two, ordering the guideline-backed tests promptly, explaining what each result does and does not mean, and coordinating with a reproductive endocrinologist when treatment is needed. If you are choosing between clinician types, see integrative GYN vs. functional medicine vs. naturopath; ovulation induction, imaging and IVF referrals need a clinician with full prescribing and ordering authority.

03Luteal phase defect and progesterone timing: what the evidence shows

Luteal phase defect means a progesterone-producing corpus luteum that is too weak or too short-lived to support implantation. It sounds simple, but ASRM’s committee opinion concludes that no reproducible, clinically practical test can diagnose it, and that treating it has not been shown to improve natural-cycle pregnancy rates.

Why the tests fail

• Progesterone is released in pulses, so a single blood level can swing several-fold within hours.
• Endometrial biopsy dating, once the standard, does not separate fertile from infertile women.
• A short luteal phase on a home chart can be normal variation.

What a mid-luteal progesterone above about 3 ng/mL (84144) reliably does is confirm that you ovulated. Many clinicians like to see about 10 ng/mL or more, but that is a practitioner target, not a validated fertility threshold.

Where progesterone does help

• IVF and frozen embryo transfer cycles: luteal-phase progesterone support is standard and clearly beneficial, because the stimulation process disrupts natural corpus luteum function.
• Early-pregnancy bleeding after prior miscarriage: in the PRISM trial, vaginal micronized progesterone 400 mg twice daily did not significantly change outcomes overall, but in women with three or more previous miscarriages, live births rose from 57% to 72%. NICE and ESHRE support offering it to women with bleeding and a prior loss.

Where it does not

The PROMISE trial found that starting progesterone in unexplained RPL, without bleeding, did not improve live birth rates. Taking progesterone “just in case” before pregnancy is confirmed can also delay periods and mask a negative cycle.

The practical timing message: confirm ovulation, treat anovulation if present (letrozole is first line in PCOS), and plan vaginal progesterone to start at the first sign of bleeding in an early pregnancy if you have had prior losses. If your cycles are irregular after stopping hormonal contraception, start with the post-pill recovery playbook.

04The couple workup: CPT codes, ICD-10 and target ranges

Common ICD-10 codes: N97.9 (female infertility, unspecified), N97.0 (infertility associated with anovulation), N96 (recurrent pregnancy loss, when not pregnant), Z31.41 (fertility testing), Z31.430 (female carrier testing), Z31.441 (testing of male partner of a patient with RPL) and N46.9 (male infertility). Tests marked RPL are for recurrent loss, not routine infertility.

Table 1 · Ranges vary by lab. Practitioner targets are working goals, not validated cut-offs. Codes must match documented history and findings; carrier screening and immunity codes vary by payer.

Not recommended routinely by ASRM or ESHRE: inherited thrombophilia panels (unless you have a personal or strong family history of clots), natural killer cell testing, HLA typing and 24-hour urine hormone panels. Price the panel with the lab cost builder fertility preset.

05Prescription and nutraceutical protocol for both partners

Prescriptions with strong evidence

• Folic acid 400–800 mcg daily for at least one month before conception (USPSTF), or 4 mg with a prior neural tube defect. Choose a prenatal with 150 mcg iodine (American Thyroid Association).
• Letrozole is first-line ovulation induction for PCOS-related anovulation (used off-label in the US); see the PCOS playbook.
• Ovarian stimulation with IUI for three to four cycles, then IVF, is ASRM’s recommended path for unexplained infertility.
• Low-dose aspirin plus prophylactic heparin in pregnancy is standard for confirmed obstetric antiphospholipid syndrome.
• Levothyroxine for TSH above about 4 mIU/L. For TSH 2.5–4 or positive TPO antibodies with normal TSH, the TABLET trial showed no live birth benefit; ASRM considers treatment optional. See the thyroid-ovarian axis playbook.
• Vaginal progesterone at the first sign of early-pregnancy bleeding if you have had prior miscarriages.

Egg-quality nutraceuticals (limited evidence)

• Coenzyme Q10, 200–600 mg daily for at least 60–90 days — a small randomized trial in women with low ovarian reserve before IVF found more eggs retrieved and better embryo quality with 600 mg; live birth data are thin. The 2020 Cochrane review of antioxidants for female subfertility rated evidence low quality.
• N-acetylcysteine (NAC), 600–1,200 mg — small trials suggest improved ovulation alongside clomiphene in PCOS; evidence is limited and not superior to metformin.
• Myo-inositol — may support ovulation in PCOS, but the 2023 international PCOS guideline calls it experimental.
• Vitamin D — correct deficiency; trials of supplementation for fertility outcomes are mixed.
• Omega-3 (DHA) — reasonable in pregnancy planning; fertility benefit unproven.

Sperm-quality support (be realistic)

Two large NIH-funded trials are sobering: the MOXI trial found a multi-antioxidant formula did not improve semen parameters or live birth, and the FAZST trial found folic acid plus zinc did not improve semen quality or live birth. A reasonable, low-cost approach is a standard multivitamin, no smoking or vaping, limited alcohol and cannabis, a healthy weight and avoiding heat exposure. Critically, testosterone or anabolic steroids suppress sperm production and should be stopped; a urologist can advise on recovery.

Shared basics for both partners: caffeine under about 200 mg a day, no smoking, and blood pressure, glucose and weight addressed before conception. Before buying a bundled “fertility stack,” review the supplement dispensary markup audit.

06Autoimmune screening and add-ons before IVF: what is worth paying for

Before IVF, the autoimmune tests with guideline support are narrow:

• Thyroid (TSH, TPO antibodies) — recommended; treat overt and clear subclinical hypothyroidism.
• Antiphospholipid antibodies — after recurrent loss, prior unexplained late loss, severe early preeclampsia or a history of blood clots. Not routine for every IVF patient.
• Celiac serology — if you have symptoms, iron deficiency or a family history; not routine.

Commonly sold add-ons with weak or negative evidence, according to ASRM, ESHRE and the UK fertility regulator’s add-on ratings:

• Natural killer cell testing and immune treatments such as IVIG, intralipid infusions or steroids for “immune infertility” — not recommended outside research; costs can reach thousands of dollars.
• Endometrial receptivity testing — randomized trials have not shown higher live birth rates for most patients.
• Endometrial scratching — no consistent benefit in large trials.
• Routine sperm DNA fragmentation testing — may help explain some cases; ESHRE allows it for explanatory purposes after RPL, but evidence that acting on it improves outcomes is limited.
• Embryo genetic testing (PGT-A) — reduces transfers in some groups but has not been shown to raise cumulative live birth rates for all patients; discuss carefully.

Where integrative care adds value before IVF is in the unglamorous basics: correcting thyroid, glucose and vitamin D, treating identifiable problems such as uterine polyps, optimizing weight and sleep, stopping smoking for both partners, and giving CoQ10 a fair 60–90 day window if you choose to try it. Those steps cost hundreds, not thousands, and none delays a referral to a reproductive endocrinologist when age or test results call for one.

07What a 12-month preconception plan costs

The range is wide because an RPL workup and ovulation induction add the most. The table excludes IUI (about $300–$1,000 per cycle plus medication) and IVF (about $15,000–$25,000 per cycle including medication, IntegrativeGyn.com estimate). The insurance-hybrid column assumes diagnostic tests through your plan with documented codes; coverage for infertility treatment depends heavily on your state and employer.

Table 2 · Typical 2026 ranges and IntegrativeGyn.com estimates. Commercial allowables run about $260–$485 for 99205 and $195–$365 for 99215; 99404 preventive counselling linked to Z31.69 may be reimbursable with modifier 25 on the E/M code. Confirm prices with your clinic and plan.

Diagnostic testing is covered far more often than treatment, so running the workup through insurance first is usually the biggest saving. The superbill and HSA/FSA guide explains preventive counselling codes, and the superbill calculator preset estimates your net visit cost.

Before paying cash for treatment, ask your employer’s benefits team directly whether your plan includes fertility benefits. About two dozen states have some form of fertility coverage law, but self-funded employer plans are often exempt, and some employers add fertility benefits voluntarily. HSA and FSA funds can usually be used for fertility testing, treatment and prescription medications.

This page is educational and is not individual medical advice; discuss your own situation with a licensed clinician.